LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of metastatic melanoma
• * Unresectable disease
• * Progressive disease while receiving standard therapy (e.g., interleukin-2 or dacarbazine)
• HLA-A0201 positive
• Measurable disease
• The following are not allowed:
• * Resectable local/regional disease
• * Patients whose serum neutralizes LMB-2 in tissue culture, due either to antitoxin or antimouse-immunoglobulin G antibodies (\> 75% of the activity of 1 ug/mL of LMB-2)
• * Received LMB-2 on another trial
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Life expectancy more than 3 months
• WBC ≥ 3,000/mm\^3
• Absolute lymphocyte count \> 500/mm\^3
• Platelet count ≥ 90,000/mm\^3
• Bilirubin ≤ 2.0 mg/dL (≤ 3.0 mg/dL for patients with Gilbert's syndrome)
• AST and ALT ≤ 2.5 times normal
• Albumin ≥ 3.0 g/dL
• No hepatitis B surface antigen or hepatitis C positivity
• Creatinine ≤ 1.4 mg/dL
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No ongoing or active infection
• Ejection fraction ≥ 45% by echocardiogram or thallium stress test (for patients \> 50 years of age OR who have a history of cardiovascular disease)
• LVEF ≥ 45%
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• No psychiatric illness or social situation that would preclude study compliance
• No other uncontrolled illness
• No known HIV positivity
• No autoimmune disease
• No immunodeficiency
• No other malignancies
• Must be willing to undergo leukapheresis
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• More than 12 weeks since prior monoclonal antibody therapy
• More than 3 weeks since prior and no concurrent systemic therapy for cancer
• No concurrent chronic anticoagulant therapy
• No concurrent systemic steroid therapy